Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > All Formal NR are on Sedar
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(73)
•••
Comment by Captainblkon Feb 03, 2021 2:27pm
126 Views
Post# 32460419

RE:All Formal NR are on Sedar

RE:All Formal NR are on Sedar
HighSkies2019 wrote: All formal legit NR are on sedar ...which are clearance from the BCSC ..OSC ..FFCTO removed and application to TSXV to get reinstated .... as for Maxwell he had a reply from Rob to him via email..and posted below yesterday evening ...I consider love letters from Rob in between .... that's why I said its best to see what NR come out from Kly ....


yup real or not, i conisder all non publically posted love notes like those to be full of poopoo. for example, Elon Musk just sent me this interesting little update in my inbox:

My Dearest CaptainBlk,

It feels as though it has been ages since we last spoke. I have transferred the majority of shares to your account, there should be a press release soon on the Tokyo Stock exchange any day now. I have also weaponized your personal satillite linked directly to your tesla. Feel free to use it on the next person to cut you off and let me know what you think, I am open to any improvments.

On a more personal note, are we still on for you to cuck my wife this weekend? we can set it up right after  the NR comes out.

yours truly, 

Elon "MoneyBags" Musk
123 A Real Place and No.
403-266-1234
elon@nigerianprince.ca
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities